- Annual report 2008 February 19, 2009
- Annual General Meeting March 27, 2009
Den Sorte Diamant 4.00 p.m.
Søren Kierkegaards Plads
1221 Copenhagen K, Denmark
- Three-month interim report (Q1) 2009 May 1, 2009
- Six-month interim report (Q2) 2009 August 18, 2009
- Nine-month interim report (Q3) 2009 November 19, 2009
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Per Plotnikof, Head of Investor Relations, tel. +45 4574 7527
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
treatment, prevention and diagnosis. Our mission is to improve quality of life
for allergic people by developing pharmaceutical products that target the
actual cause of allergy. ALK is the world leader in allergy vaccination
(immunotherapy) - a unique treatment that induces a protective immune response
which reduces and potentially halts the allergic reaction. Allergy vaccination
is traditionally administered as subcutaneous injections or sublingual
droplets. Our aim is to extend the use of allergy vaccination by introducing
convenient, tablet-based vaccines, thereby offering many more patients a causal
allergy treatment. Following this strategy, the world's first tablet-based
vaccine against grass pollen allergy, GRAZAX®, was launched in Europe in 2007.
ALK has entered into a strategic partnership regarding the tablet programme
with Schering-Plough for North America. ALK has approximately 1,500 employees
with subsidiaries, production facilities and distributors worldwide. The
company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX
Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory
Copenhagen (København)'. Further information is available at www.alk-abello.com
and www.GRAZAX.com.
